Reticulocyte dynamic and hemoglobin variability in hemodialysis patients treated with Darbepoetin alfa and C.E.R.A.: a randomized controlled trial

Table 2 Blood parameter, treatment dose and variability (MSSD) of Period 1–2 (Q4W ESAs administration interval)

	C.E.R.A	Darbepoetin alfa	p-value
	(n = 30)	(n = 30)	p-value
Hemoglobin, g/dl (mean, SD)	11.3 (0.2)	11.2 (0.2)	0.65
Reticulocyte count, cells/μl (mean, SD)	69891 (18153)	67047 (18038)	0.55
Ferritin, μg/l (mean, SD)	438.7 (190.8)	429.9 (142.7)	0.84
Cumulated ESA dose, μg (mean, SD)	788.1 (554.6)	867.9 (721.4)	0.65
Cumulated iron dose, μg (mean, SD)	703.7 (325)	781.5 (306.4)	0.37
ST-MSSD Hb, g ² /dl ² (mean, SD)	0.57 (0.58)	0.52 (0.38)	0.73
LT-MSSD Hb, g ² /dl ² (mean, SD)	0.62 (0.47)	0.32 (0.36)	0.009
ST-MSSD Ret, cells ² /μl ² (mean, SD)	26.9x10⁸ (28.2x10⁸)	37.8x10⁸ (36.1x10⁸)	0.20
LT-MSSD-Ret, cells ² /μl ² (mean, SD)	4.8x10⁸ (5.7x10⁸)	2.5x10⁸ (4.6x10⁸)	0.14

ISSN: 1471-2369